8-K

                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549


                                 ______________


                                    FORM 8-K

                                 CURRENT REPORT

                         Pursuant to Section 13 or 15(d)
                     of the Securities Exchange Act of 1934

                                 ______________


        Date of Report (Date of earliest event reported): October 2, 2002

                            ORCHID BIOSCIENCES, INC.
             (Exact name of registrant as specified in its charter)


     Delaware                    000-30267                    22-3392819
- -----------------            ---------------             ----------------------
(State or other                (Commission                   (IRS Employer
jurisdiction of                File Number)                Identification No.)
incorporation)


                                4390 US Route One
                               Princeton, NJ 08540
               --------------------------------------------------
               (Address of principal executive offices) (Zip Code)


       Registrant's telephone number, including area code: (609) 750-2200


                                 Not Applicable
          -------------------------------------------------------------
          (Former name or former address, if changed since last report)



Item 5.   Other Events.


On October 2, 2002, Orchid BioSciences, Inc. ("Orchid") announced that it had
appointed Andrew P. Savadelis to the position of chief financial officer and
senior vice president of finance to fortify its management team as Orchid
implements its strategic and operational plans through 2003. Mr. Savadelis
filled the position previously held by Donald R. Marvin, who served in the dual
roles of chief financial officer for Orchid BioSciences and as general manager
of Orchid Diagnostics. Mr. Marvin will continue as head of Orchid Diagnostics,
focusing his full attention on the ongoing development and growth of this
strategic business unit.

The information contained in the press release which is attached as Exhibit 99.1
is incorporated by reference as if set forth fully herein.

Item 7.   Financial Statements and Exhibits

(c)      Exhibits.

         99.1    Press Release dated October 2, 2002.


                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                            ORCHID BIOSCIENCES, INC.
                                            (Registrant)

Date:  October 17, 2002                     /s/ Dale R. Pfost
                                            ------------------------------
                                            Name:  Dale R. Pfost
                                            Title: President and CEO



                                  EXHIBIT INDEX

Exhibit
Number            Description
- -------           -----------

99.1              Press release dated October 2, 2002.

EX-99.1

                                                                    Exhibit 99.1

FOR IMMEDIATE RELEASE

Contact:
Orchid BioSciences, Inc.
(609) 750-2200
Tracy J. Henrikson
Director, Corporate Communications

                 ORCHID BIOSCIENCES APPOINTS ANDREW P. SAVADELIS
                             CHIEF FINANCIAL OFFICER

PRINCETON, N.J., Oct. 2, 2002 -- Orchid BioSciences, Inc. (Nasdaq: ORCH) today
announced that it has appointed Andrew P. Savadelis to the position of chief
financial officer and senior vice president of finance to fortify its management
team as the company implements its strategic and operational plans through 2003.
Mr. Savadelis fills the position previously held by Donald R. Marvin, who has
served in the dual roles of chief financial officer for Orchid BioSciences and
as general manager of Orchid Diagnostics. Mr. Marvin will continue as head of
Orchid Diagnostics, focusing his full attention on the ongoing development and
growth of this strategic business unit.

"Our appointment of a new chief financial officer reflects Orchid's ongoing
progress in its commitment to continue our strong growth and achieve
profitability by the end of next year," said Dale R. Pfost, Ph.D., chairman,
president and chief executive officer of Orchid. "Orchid has expanded
considerably over the last two years through both organic and acquired growth
and now is an international company with four major business units based on DNA
testing. This presents new opportunities for Orchid, and we believe that
Andrew's appointment will strengthen our ability to successfully address our
next phase of growth. We are pleased that Andrew, an individual with financial
management experience in both the global pharmaceutical and innovative
technology industries, is joining Orchid as CFO."

Mr. Savadelis has more than 15 years of experience in corporate finance,
governance, and merger and acquisition activities for high growth and
pharmaceutical companies. Most recently, he was principal of Stratus Photonics,
Inc., a developer of optical signal conditioning and routing modules. From
September 2000 to January 2002, Mr. Savadelis served as chief financial officer
and executive vice president of finance for eMagin Corporation, an innovative
imaging display technology company. Previously, for seven years he was at
Anadigics, Inc., a manufacturer of radio frequency integrated circuits solutions
for wireless and broadband communications markets, where he most recently served
as treasurer, assistant secretary and senior director of mergers and
acquisitions. Prior to joining Anadigics, he spent seven years at Bristol-Myers
Squibb, where he held positions of increasing responsibility in the financial
area. Mr. Savadelis has a B.S. in Biology from Albright College and an MBA from
the Johnson Graduate School of Management at Cornell University.



About Orchid BioSciences
Orchid BioSciences is the leading provider of services and products for DNA
diversity testing. Orchid's four interlocking strategic business units address
distinctive markets that together represent a unique balance of established,
predictable growth, like identity genomics, and large upside potential, like
personalized healthcare. All leverage Orchid's network of accredited genotyping
laboratories, its leading technologies and its expertise in genetic diversity
analysis. Orchid provides identity genomics testing for forensics and paternity
through Orchid Cellmark and Orchid GeneScreen. Orchid Diagnostics markets
products and services for HLA genotyping, disease susceptibility testing and
immunogenetics. Orchid GeneShield is developing pharmacogenetics-based programs
designed to accelerate the adoption of personalized healthcare. Orchid Life
Sciences provides advanced SNP genotyping services to pharmaceutical,
biotechnology, agricultural and academic customers and collaborators, and
develops valuable SNP markers and assays. More information on Orchid can be
found at its web site www.orchid.com.

All statements in this press release that are not historical are forward-looking
statements within the meaning of Section 21E of the Securities Exchange Act as
amended, including statements regarding Orchid's belief that Andrew Savadelis'
appointment will strengthen its ability to successfully address Orchid's next
phase of growth. Such statements are subject to risks and uncertainties that
could cause actual results to differ materially from those projected, including,
but not limited to, uncertainties relating to technologies, product development,
manufacturing, market acceptance, cost and pricing of Orchid products and
services, dependence on collaborations and partners, regulatory approvals,
competition, intellectual property of others, and patent protection and
litigation. These risks and other additional factors affecting Orchid's business
are discussed in the "Forward-Looking Statements" section of Orchid's Form 10-Q
for the quarterly period ended June 30, 2002 and the "Overview" and "Risk
Factors" sections of Orchid's Annual Report on Form 10-K for the year ended
December 31, 2001, filed with the Securities and Exchange Commission. Orchid
expressly disclaims any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements contained herein to
reflect any change in Orchid's expectations with regard thereto or any change in
events, conditions, or circumstances on which any such statements are based,
except as may be required by law.

                                       ###